The document summarizes the current state and future prospects of the health care industry in Russia and the region of Tatarstan. It outlines that the Russian market is large and growing, with an aging population driving increased demand. The government is undertaking major reforms through 2020 to encourage local production, R&D, and increase spending. This includes legal changes favoring domestic manufacturers and 4.2 billion in investments. The region of Tatarstan is highlighted as a success story within Russia's health care industry.
The greatest challenges in Russian health careBachinskaya
The document discusses upcoming challenges and changes to healthcare in Russia between 2013-2014 and through 2020. Key points include:
1) Decentralization of essential drug programs and regional budget calculations based on per capita spending will occur by 2014.
2) A National Drug Insurance program will be piloted in 2014 and implemented between 2015-2016.
3) Four main innovations will ensure competitiveness of the new healthcare system, including standardized care measures, single-channel financing, expanded financing for select medical institutions, and strengthened regional autonomy.
4) Healthcare financing will shift to a Unified National Funding Organization supported by government budget and national insurance with reduced personal expenses.
- Two decades ago, Kazakhstan's healthcare system was on the verge of collapse and was reformed extensively, including building new hospitals, training healthcare professionals abroad, and investing in new medical equipment.
- The government aims to diversify away from heavy reliance on energy industries and developed strategies focusing on sectors like chemicals, pharmaceuticals, agriculture, and transportation.
- Reforms included establishing a national pharmaceutical distributor, supporting local drug manufacturers, and providing free medical aid for priority health areas through a state reimbursement system based on annual tenders.
The pharmaceutical market of Uzbekistan is growing rapidly due to economic development and population growth. The market is currently estimated at $650-700 million but is forecast to double to $1.5 billion by 2020. Local manufacturers currently hold 20% market share while the remaining 80% is held by foreign manufacturers, primarily from Europe, the US, and India. The government is supporting development of domestic production through incentives for foreign investment. Key growth areas are expected to be generics, OTC drugs, and patented brands as consumer purchasing power increases. The market remains underdeveloped with a need for more modern medical facilities and a wider range of products across the country.
The Report uncovers 2019 FY business trends of the pharmaceutical market in Russia, reviews its healthcare system, portrays its epidemiology and demographics. It also depicts pharma regulation features in Russia including a step-by-step process of the marketing authorization procedure for pharma products. It offers insight into the country’s sociopolitical development since independence, describes recent economic trends, and provides the local pharmaceutical sales forecast for the next three years (2019-2021).
The Commonwealth of Independent States (CIS) region has a total GDP of approximately $1.6 trillion and a population of 276 million people. While the original drug market will grow more slowly than generics between 2010-2011, overall growth in original medicines will be positive. The pharmaceutical market is dominated by generic drugs, which make up around 85% of the market. Key players and market structure differ from Western markets, with almost a 50/50 split between Rx and OTC segments and strong local generic production, particularly in Ukraine.
The document summarizes the Ukrainian pharmaceutical market and reasons for starting a business there. It notes that Ukraine has a large pharmaceutical market with over $2.8 billion in retail sales in 2019. The market is growing in both monetary and physical terms. Foreign manufacturers are increasing their market share. Ukraine also offers low costs for doing business, a large workforce, and natural attractions for tourism. The agency provides various consulting services to help companies enter and succeed in the Ukrainian pharmaceutical market.
Uzbekistan Pharmaceutical Country Report 9M 2019Eirhub
The Report uncovers 9M 2019 business trends of the pharmaceutical market in Uzbekistan, reviews its healthcare system, portrays its epidemiology and demographics. It also depicts pharma regulation features in Uzbekistan including a step-by-step process of the marketing authorization procedure for pharma products. It offers insight into the country’s sociopolitical development since independence, describes recent economic trends, and provides the local pharmaceutical sales forecast for the next three years (2019-2021).
The greatest challenges in Russian health careBachinskaya
The document discusses upcoming challenges and changes to healthcare in Russia between 2013-2014 and through 2020. Key points include:
1) Decentralization of essential drug programs and regional budget calculations based on per capita spending will occur by 2014.
2) A National Drug Insurance program will be piloted in 2014 and implemented between 2015-2016.
3) Four main innovations will ensure competitiveness of the new healthcare system, including standardized care measures, single-channel financing, expanded financing for select medical institutions, and strengthened regional autonomy.
4) Healthcare financing will shift to a Unified National Funding Organization supported by government budget and national insurance with reduced personal expenses.
- Two decades ago, Kazakhstan's healthcare system was on the verge of collapse and was reformed extensively, including building new hospitals, training healthcare professionals abroad, and investing in new medical equipment.
- The government aims to diversify away from heavy reliance on energy industries and developed strategies focusing on sectors like chemicals, pharmaceuticals, agriculture, and transportation.
- Reforms included establishing a national pharmaceutical distributor, supporting local drug manufacturers, and providing free medical aid for priority health areas through a state reimbursement system based on annual tenders.
The pharmaceutical market of Uzbekistan is growing rapidly due to economic development and population growth. The market is currently estimated at $650-700 million but is forecast to double to $1.5 billion by 2020. Local manufacturers currently hold 20% market share while the remaining 80% is held by foreign manufacturers, primarily from Europe, the US, and India. The government is supporting development of domestic production through incentives for foreign investment. Key growth areas are expected to be generics, OTC drugs, and patented brands as consumer purchasing power increases. The market remains underdeveloped with a need for more modern medical facilities and a wider range of products across the country.
The Report uncovers 2019 FY business trends of the pharmaceutical market in Russia, reviews its healthcare system, portrays its epidemiology and demographics. It also depicts pharma regulation features in Russia including a step-by-step process of the marketing authorization procedure for pharma products. It offers insight into the country’s sociopolitical development since independence, describes recent economic trends, and provides the local pharmaceutical sales forecast for the next three years (2019-2021).
The Commonwealth of Independent States (CIS) region has a total GDP of approximately $1.6 trillion and a population of 276 million people. While the original drug market will grow more slowly than generics between 2010-2011, overall growth in original medicines will be positive. The pharmaceutical market is dominated by generic drugs, which make up around 85% of the market. Key players and market structure differ from Western markets, with almost a 50/50 split between Rx and OTC segments and strong local generic production, particularly in Ukraine.
The document summarizes the Ukrainian pharmaceutical market and reasons for starting a business there. It notes that Ukraine has a large pharmaceutical market with over $2.8 billion in retail sales in 2019. The market is growing in both monetary and physical terms. Foreign manufacturers are increasing their market share. Ukraine also offers low costs for doing business, a large workforce, and natural attractions for tourism. The agency provides various consulting services to help companies enter and succeed in the Ukrainian pharmaceutical market.
Uzbekistan Pharmaceutical Country Report 9M 2019Eirhub
The Report uncovers 9M 2019 business trends of the pharmaceutical market in Uzbekistan, reviews its healthcare system, portrays its epidemiology and demographics. It also depicts pharma regulation features in Uzbekistan including a step-by-step process of the marketing authorization procedure for pharma products. It offers insight into the country’s sociopolitical development since independence, describes recent economic trends, and provides the local pharmaceutical sales forecast for the next three years (2019-2021).
The pharmaceutical industry in Ukraine is growing rapidly but domestic production cannot keep up with market demands. Ukraine has a large population and territory, making it an attractive market for foreign pharmaceutical companies. The retail pharmaceutical market grows over 14% annually, fueled by increasing drug prices, though hospital segment growth is limited by state financing problems. Domestic producers focus on cheap mass drugs while foreign companies dominate the higher value market. AlexPharm is a Ukrainian pharmaceutical company established in 1994 as a joint venture with Pfizer. It markets over 30 products in therapeutic areas like gynecology, urology and cardiology through sales representatives and promotional activities. The company partners with major international pharmaceutical producers.
Latvijas Banka Monthly Newsletter: July 2018Latvijas Banka
Highlights:
Energy pushes consumer prices upward
Household lending increased in May
Growth in goods exports continued in May
In Focus:
Competitiveness of Latvia's Exports of Goods in the Region
This document is a monthly report on the Ukrainian pharmaceutical market from March 2016. It provides key macroeconomic indicators for Ukraine from February 2015 to February 2016, including GDP growth, export/import levels, unemployment, and exchange rates. It also gives pharmaceutical industry-specific data over the same time period, such as export/import of pharmaceutical products, retail sales volumes and values, weighted average cost per pack, and the market share of local vs. foreign companies. The report concludes with a summary of recent economic events in Ukraine.
This whitepaper provides an overview of Chinese pharmaceutical market access. This includes an overview of the Chinese pharmaceutical market, government regulatory bodies,distribution channels, demographics, pricing and insurance. It also includes an overview of current regulations and product registration procedures.
This paper is meant for anyone within the pharmaceutical industry who is looking to learn more about how to access the pharmaceutical market in China.
For more information, contact us for a free 15 minute consultation at http://www.pacificbridgemedical.com/contact-us/.
The document summarizes key findings from interviews with Russian pharmaceutical producers, experts, and officials about challenges in implementing Russia's "Pharma 2020 Strategy". The strategy aims to transition Russia's pharmaceutical industry to an innovation model by 2020, but experts expressed skepticism about whether the strategy's methods can attract needed investment. While some targets like 50-60% localized production seem unrealistic, over 50% of experts still support the strategy for ensuring Russia's "biological security". However, the funds allocated are unlikely to cover costs, and obstacles to exports may limit returns on investment in domestic production. Effective use of allocated funds will be important for the strategy's success.
The document discusses a report on the healthcare market that a government employee is preparing for their country. It provides context on healthcare challenges faced by aging populations and increasing costs. The employee is considering privatizing healthcare by having individuals pay providers directly. Their report will use economic terms to analyze demand, supply, market failures and government interventions in healthcare markets. It will draw on examples from the UK and other sources to make policy recommendations.
National health accounts - Ali Nurgozhayev, KazakhstanOECD Governance
This presentation was made by Ali Nurgozhayev, Kazakhstan, at the 2nd Health Systems joint Network Meeting for Central, Eastern and Southeastern European Countries held in Tallinn, Estonia, on 1-2 December 2016
Swedbank was founded in 1820, as Sweden’s first savings bank was established. Today, our heritage is visible in that we truly are a bank for each and every one and in that we still strive to contribute to a sustainable development of society and our environment. We are strongly committed to society as a whole and keen to help bring about a sustainable form of societal development. Our Swedish operations hold an ISO 14001 environmental certification, and environmental work is an integral part of our business activities.
This document provides an overview of the Ukrainian pharmaceutical market and macroeconomic environment in December 2015. It discusses key economic events in Ukraine, including approval of the 2016 budget and tax code. Macroeconomic indicators such as GDP, exports, imports, currency exchange rates, unemployment, and salaries are presented. The pharmaceutical industry section provides data on export and import of pharmaceutical products, retail pharmacy sales volumes and values, and consumer price indexes. Local pharmaceutical companies' market share is also indicated.
This is a demo version of Williams & Marshall Strategy's report on the ethylene oxide market in the Scandinavian countries. The report presents a strategic analysis of the ethylene oxide market in the region and a forecast for its development in the medium term. It provides a comprehensive overview of the market, its dynamics, structure, characteristics, main players, growth and demand drivers, etc. This is the most detailed and comprehensive report about the ethylene oxide market in the Scandinavian countries currently available!
This is a demo version of Williams & Marshall Strategy's report on the ethylene oxide market in Central and Eastern Europe. The report presents a strategic analysis of the ethylene oxide market in the region and a forecast for its development in the medium term. It provides a comprehensive overview of the market, its dynamics, structure, characteristics, main players, growth and demand drivers, etc. This is the most detailed and comprehensive report about the ethylene oxide market in Central and Eastern Europe currently available!
This report provides updated facts and figures on the evolution of the national energy market. For the oil, gas, coal and power markets, the report details the market organisation, institutions regulating the market, and energy policy of the country. Energy companies active on the market are analysed. Domestic production, capacities, exchanges, consumption by sector and market shares are provided. Energy prices levels and taxes are described. Finally, the driving issues, and the market prospects are proposed.
In this presentation to some of the United States largest medical device manufacturers; many whom were eager to enter this seemingly insatiable market, we demonstrated some of the key risks and corresponding potential rewards of this awakening giant. Specifically we highlighted;
* The size and structure of the market
* Key growth drivers, including government-directed
initiatives from the healthcare reform and the 12th Five
Year Plan
* Companies in the market – international and domestic
and the lessons learned from their efforts to expand
geographically beyond the Tier 1-2 coastal hubs
* The immense economic and healthcare infrastructure
differences across China, and how that impacts the
companies’ go-to-market decisions and the surgeon and
patient product preferences
* Some key operational and regulatory constraints and
considerations in what is often an opaque operating
environment
* Some of the strategies embedded firms are utilising as
they move "Westward"
China chemical medicine preparation industry production & marketing demand an...Qianzhan Intelligence
This document provides an overview and analysis of the chemical medicine preparation industry in China. It begins with definitions of key terms and classifications of products in the industry. It then analyzes the development environment, size, profitability, import/export markets, and competitive landscape of the industry. It also examines the industry supply chain, development trends, and leading companies. The document aims to help readers understand the current state and future prospects of China's chemical medicine preparation industry.
China chemical medicine preparation industry production & marketing demand an...Qianzhan Intelligence
This document provides an overview and analysis of the chemical medicine preparation industry in China. It begins with definitions of key terms and classifications of products in the industry. It then analyzes the development environment, size, profitability, import/export markets, and competitive landscape of the industry. It also examines the industry supply chain, development trends, and leading companies. The document aims to help readers understand the current state and future prospects of China's chemical medicine preparation industry.
China chemical medicine preparation industry production & marketing demand an...Qianzhan Intelligence
This document provides an overview and analysis of the chemical medicine preparation industry in China. Some key points:
9
Chemical Medicine Preparation Industry
1. The chemical medicine preparation industry is an important part of China's pharmaceutical industry and national economy. It has experienced rapid growth in recent years.
2. The industry is in a competitive stage and faces opportunities as well as challenges. Domestic brands are gradually entering the high-end market while foreign brands still dominate.
3. The report analyzes the industry's development environment, economic indicators, supply and demand, market competition, major product markets, and forecasts future trends. It aims to help industry players make wise decisions.
China chemical medicine preparation industry production & marketing demand an...Qianzhan Intelligence
This document provides an overview and analysis of the chemical medicine preparation industry in China. It begins with definitions of key terms and classifications of products in the industry. It then analyzes the development environment, size, profitability, import/export markets, and competitive landscape of the industry. It also examines the industry supply chain, development trends, and leading companies. The document aims to help readers understand the current state and future prospects of China's chemical medicine preparation industry.
The pharmaceutical industry in Ukraine is growing rapidly but domestic production cannot keep up with market demands. Ukraine has a large population and territory, making it an attractive market for foreign pharmaceutical companies. The retail pharmaceutical market grows over 14% annually, fueled by increasing drug prices, though hospital segment growth is limited by state financing problems. Domestic producers focus on cheap mass drugs while foreign companies dominate the higher value market. AlexPharm is a Ukrainian pharmaceutical company established in 1994 as a joint venture with Pfizer. It markets over 30 products in therapeutic areas like gynecology, urology and cardiology through sales representatives and promotional activities. The company partners with major international pharmaceutical producers.
Latvijas Banka Monthly Newsletter: July 2018Latvijas Banka
Highlights:
Energy pushes consumer prices upward
Household lending increased in May
Growth in goods exports continued in May
In Focus:
Competitiveness of Latvia's Exports of Goods in the Region
This document is a monthly report on the Ukrainian pharmaceutical market from March 2016. It provides key macroeconomic indicators for Ukraine from February 2015 to February 2016, including GDP growth, export/import levels, unemployment, and exchange rates. It also gives pharmaceutical industry-specific data over the same time period, such as export/import of pharmaceutical products, retail sales volumes and values, weighted average cost per pack, and the market share of local vs. foreign companies. The report concludes with a summary of recent economic events in Ukraine.
This whitepaper provides an overview of Chinese pharmaceutical market access. This includes an overview of the Chinese pharmaceutical market, government regulatory bodies,distribution channels, demographics, pricing and insurance. It also includes an overview of current regulations and product registration procedures.
This paper is meant for anyone within the pharmaceutical industry who is looking to learn more about how to access the pharmaceutical market in China.
For more information, contact us for a free 15 minute consultation at http://www.pacificbridgemedical.com/contact-us/.
The document summarizes key findings from interviews with Russian pharmaceutical producers, experts, and officials about challenges in implementing Russia's "Pharma 2020 Strategy". The strategy aims to transition Russia's pharmaceutical industry to an innovation model by 2020, but experts expressed skepticism about whether the strategy's methods can attract needed investment. While some targets like 50-60% localized production seem unrealistic, over 50% of experts still support the strategy for ensuring Russia's "biological security". However, the funds allocated are unlikely to cover costs, and obstacles to exports may limit returns on investment in domestic production. Effective use of allocated funds will be important for the strategy's success.
The document discusses a report on the healthcare market that a government employee is preparing for their country. It provides context on healthcare challenges faced by aging populations and increasing costs. The employee is considering privatizing healthcare by having individuals pay providers directly. Their report will use economic terms to analyze demand, supply, market failures and government interventions in healthcare markets. It will draw on examples from the UK and other sources to make policy recommendations.
National health accounts - Ali Nurgozhayev, KazakhstanOECD Governance
This presentation was made by Ali Nurgozhayev, Kazakhstan, at the 2nd Health Systems joint Network Meeting for Central, Eastern and Southeastern European Countries held in Tallinn, Estonia, on 1-2 December 2016
Swedbank was founded in 1820, as Sweden’s first savings bank was established. Today, our heritage is visible in that we truly are a bank for each and every one and in that we still strive to contribute to a sustainable development of society and our environment. We are strongly committed to society as a whole and keen to help bring about a sustainable form of societal development. Our Swedish operations hold an ISO 14001 environmental certification, and environmental work is an integral part of our business activities.
This document provides an overview of the Ukrainian pharmaceutical market and macroeconomic environment in December 2015. It discusses key economic events in Ukraine, including approval of the 2016 budget and tax code. Macroeconomic indicators such as GDP, exports, imports, currency exchange rates, unemployment, and salaries are presented. The pharmaceutical industry section provides data on export and import of pharmaceutical products, retail pharmacy sales volumes and values, and consumer price indexes. Local pharmaceutical companies' market share is also indicated.
This is a demo version of Williams & Marshall Strategy's report on the ethylene oxide market in the Scandinavian countries. The report presents a strategic analysis of the ethylene oxide market in the region and a forecast for its development in the medium term. It provides a comprehensive overview of the market, its dynamics, structure, characteristics, main players, growth and demand drivers, etc. This is the most detailed and comprehensive report about the ethylene oxide market in the Scandinavian countries currently available!
This is a demo version of Williams & Marshall Strategy's report on the ethylene oxide market in Central and Eastern Europe. The report presents a strategic analysis of the ethylene oxide market in the region and a forecast for its development in the medium term. It provides a comprehensive overview of the market, its dynamics, structure, characteristics, main players, growth and demand drivers, etc. This is the most detailed and comprehensive report about the ethylene oxide market in Central and Eastern Europe currently available!
This report provides updated facts and figures on the evolution of the national energy market. For the oil, gas, coal and power markets, the report details the market organisation, institutions regulating the market, and energy policy of the country. Energy companies active on the market are analysed. Domestic production, capacities, exchanges, consumption by sector and market shares are provided. Energy prices levels and taxes are described. Finally, the driving issues, and the market prospects are proposed.
In this presentation to some of the United States largest medical device manufacturers; many whom were eager to enter this seemingly insatiable market, we demonstrated some of the key risks and corresponding potential rewards of this awakening giant. Specifically we highlighted;
* The size and structure of the market
* Key growth drivers, including government-directed
initiatives from the healthcare reform and the 12th Five
Year Plan
* Companies in the market – international and domestic
and the lessons learned from their efforts to expand
geographically beyond the Tier 1-2 coastal hubs
* The immense economic and healthcare infrastructure
differences across China, and how that impacts the
companies’ go-to-market decisions and the surgeon and
patient product preferences
* Some key operational and regulatory constraints and
considerations in what is often an opaque operating
environment
* Some of the strategies embedded firms are utilising as
they move "Westward"
China chemical medicine preparation industry production & marketing demand an...Qianzhan Intelligence
This document provides an overview and analysis of the chemical medicine preparation industry in China. It begins with definitions of key terms and classifications of products in the industry. It then analyzes the development environment, size, profitability, import/export markets, and competitive landscape of the industry. It also examines the industry supply chain, development trends, and leading companies. The document aims to help readers understand the current state and future prospects of China's chemical medicine preparation industry.
China chemical medicine preparation industry production & marketing demand an...Qianzhan Intelligence
This document provides an overview and analysis of the chemical medicine preparation industry in China. It begins with definitions of key terms and classifications of products in the industry. It then analyzes the development environment, size, profitability, import/export markets, and competitive landscape of the industry. It also examines the industry supply chain, development trends, and leading companies. The document aims to help readers understand the current state and future prospects of China's chemical medicine preparation industry.
China chemical medicine preparation industry production & marketing demand an...Qianzhan Intelligence
This document provides an overview and analysis of the chemical medicine preparation industry in China. Some key points:
9
Chemical Medicine Preparation Industry
1. The chemical medicine preparation industry is an important part of China's pharmaceutical industry and national economy. It has experienced rapid growth in recent years.
2. The industry is in a competitive stage and faces opportunities as well as challenges. Domestic brands are gradually entering the high-end market while foreign brands still dominate.
3. The report analyzes the industry's development environment, economic indicators, supply and demand, market competition, major product markets, and forecasts future trends. It aims to help industry players make wise decisions.
China chemical medicine preparation industry production & marketing demand an...Qianzhan Intelligence
This document provides an overview and analysis of the chemical medicine preparation industry in China. It begins with definitions of key terms and classifications of products in the industry. It then analyzes the development environment, size, profitability, import/export markets, and competitive landscape of the industry. It also examines the industry supply chain, development trends, and leading companies. The document aims to help readers understand the current state and future prospects of China's chemical medicine preparation industry.
The main factor in the development of the Russian economy at present is human
capital. The capitalization of the human factor, i.e. the transformation of knowledge
into value added, is impossible without increasing innovation activity. In Russia,
despite the rather high educational level of the population, there is low innovation
activity in comparison with the leading countries. There is a clear contradiction. One
problem is the assessment of human capital. The article presents the author's method
of assessing the human capital of an innovative organization. To determine the
scenario of human capital development, a theoretical matrix is used, which
characterizes the interdependence of the level of human capital assessment and the
effectiveness of innovative activity of the organization.
1) By 2020, the Indian pharmaceutical industry is projected to grow to $50 billion and become one of the top 10 pharmaceutical markets globally, driven by strong domestic demand and increased exports.
2) Generics are expected to continue dominating the market, accounting for around 90% of the pharmaceutical formulation market. Patent-protected drugs will make up about 10% of the market.
3) Increased healthcare infrastructure investment, rising incomes, health insurance expansion, and government programs are expected to drive growth in domestic pharmaceutical demand and help increase accessibility of drugs across India. Chronic diseases will account for over half of the pharmaceutical market.
Successfully Accessing Medical Equipment Markets in CIVETS Available on Rese...QYResearchReports
The short-lived positron-emitting isotopes used in PET imaging are generally produced in a cyclotron and then synthesised on-site before patient administration. Although not requiring the use of a nuclear reactor, this limits the use of PET imaging to centres with access to a cyclotron and synthesis equipment. Therefore, a major development is the recent availability of smaller and cheaper cyclotrons which are designed to produce C-11 and F-18 isotopes economically and on-demand, without the need for radiochemistry or PET accelerator expertise.
The global sales of medicines reached $942 billion in 2011, a 5.1% increase from the previous year. This total is expected to reach $1.5 trillion by 2020 due to population growth and an aging population. However, the pharmaceutical industry faces issues such as losing $148 billion annually from 2012-2018 due to drugs going off patent and rising research and development costs of $800 million to $4 billion to bring a new drug to market. The Indian pharmaceutical industry has grown substantially over the past few decades but faces threats from increasing regulation and low-cost competition from other countries.
Dietary supplements market in Poland 2015 Development forecasts for 2015-2020Shrikant Mandlik
This document summarizes a report on the dietary supplements market in Poland from 2015-2020. It provides an overview of the size and segments of the Polish supplements market, including key distribution channels like pharmacies and non-pharmacy retailers. The report examines individual supplement categories and offers sales forecasts. It also analyzes regulatory trends, consumer behavior, and profiles major market players.
The global pharmaceutical market reached $942 billion in 2011 and is expected to reach $1.5 trillion by 2020 due to population growth and aging populations. The industry faces issues such as patent cliffs resulting in lost revenues, high research and development costs, and increasing government regulation. The Indian pharmaceutical industry has grown substantially over the past few decades and now supplies over 70% of the country's drug needs through branded generics. However, it faces weaknesses of stringent price controls, low investment in innovation, and quality concerns.
Medical devices market research Russia 2012-2014Roman Korablev
This document provides a summary of the medical devices market in Russia, including forecasts for 2015-2016. It discusses the challenging economic conditions in Russia in 2014 due to sanctions and low oil prices. This caused significant devaluation of the ruble. The document outlines several government programs that provide funding for medical device purchases and modernization of healthcare facilities. It also discusses the methodology used to analyze customs import data and segmentation of the market. Key factors like currency fluctuations and government regulations are noted as influencing the market.
China pharmaceutical excipients industry indepth research and investment stra...Qianzhan Intelligence
The document discusses the pharmaceutical excipients industry in China. It notes that the quality of excipients directly impacts the quality of pharmaceutical preparations. The development of the excipients industry in China lags behind the pharmaceutical industry. The report analyzes the industrial environment, development status, challenges, and opportunities for the Chinese excipients industry. It also compares the industry to international standards and practices. The report provides an overview of the industry's development prospects and competitive landscape.
China pharmaceutical excipients industry indepth research and investment stra...Qianzhan Intelligence
The document discusses China's pharmaceutical excipients industry. It notes that the quality of excipients directly impacts the quality of drug preparations. The development of excipients in China has lagged the pharmaceutical industry. However, recent events have brought increased attention to excipients and driven their healthy development. The report analyzes the industry's environment, market size, competitors, and prospects for development. It aims to help readers understand the industry's trends to seize opportunities and make informed decisions.
China pharmaceutical excipients industry indepth research and investment stra...Qianzhan Intelligence
The document discusses the pharmaceutical excipients industry in China. It provides an overview of the industry, including definitions and classifications of excipients. It also analyzes the industry's development environment, highlighting factors like economic conditions, policies, and technology. Internationally, the report examines major excipient-producing countries and regions, comparing management approaches. It then assesses the development, competition, and models of China's excipients industry, identifying issues and opportunities. Overall, the document conducts a comprehensive analysis of the pharmaceutical excipients sector in China and globally.
China pharmaceutical excipients industry indepth research and investment stra...Qianzhan Intelligence
The document discusses the pharmaceutical excipients industry in China. It notes that the quality of excipients directly impacts the quality of pharmaceutical preparations. It also discusses the industrial chain of the excipients industry and its interactions with the preparations industry. The excipients industry supports the development of preparations, while the preparations industry drives demand for higher quality excipients. The report aims to comprehensively analyze the current state and development trends of China's excipients industry through market data and forecasts. It covers topics such as industry scale, competition, development models, and strategies.
China pharmaceutical excipients industry indepth research and investment stra...Qianzhan Intelligence
The document discusses China's pharmaceutical excipients industry. It notes that the quality of excipients directly impacts the quality of drug preparations. The development of excipients in China has lagged the pharmaceutical industry. However, recent events have brought increased attention to excipients and driven their development. The report analyzes the industry's environment, market size, competitors, and prospects for development. It aims to provide a comprehensive overview of the current state and future trends in China's pharmaceutical excipients sector.
This document provides an overview of 50 investment projects in the Republic of Tatarstan, organized into different sectors including priority projects, chemicals and petrochemicals, machinery and automotive parts, construction and building materials, medicine and pharmaceuticals, IT and telecommunications, agriculture and food processing, service industry and tourism, and others. Specific projects are listed with details on location, estimated jobs created, total budget, financial indicators, and contacts for further information. The projects aim to develop industries, create jobs, and attract domestic and foreign investment to the Republic of Tatarstan.
Tatarstan Service Industry & Tourism (Dec 2013)InvestTatarstan
Presentation given at the Tatarstan Investment Conference: Service Industry & Tourism on 12 December 2013 in Moscow.
For more information, please visit invest.tatarstan.ru.
Kazan Smart City is a groundbreaking urban development project designed to spur the growth of investment into high technology, medicine, education, and tourism. The project is being developed using the latest advancements in urban planning and engineering.
For more information, visit www.KazanSmartCity.com or contact the Tatarstan Investment Development Agency.
An overview of the investment climate of the Republic of Tatarstan prepared by PwC in conjunction with the Tatarstan Investment Development Agency. Copyright 2013.
For more information about investing in Tatarstan, please contact the Tatarstan Investment Development Agency: tida.tatarstan.ru.
50 Investment Projects in the Republic of Tatarstan (Russia)InvestTatarstan
Prepared for KazanSummit 2013: 5th International Economic Summit of Russia and OIC Countries, this book contains 50 investment projects in eight of Tatarstan's priority investment sectors. For more information about these projects or more infomation about investment opportunities in Tatarsatn, contact the Tatarstan Investment Development Agency (tida.tatar.ru)
The Republic of Tatarstan is one of the most economically developed regions of the Russian Federation. The republic lies just 800 kilometers east of Moscow on 68 square kilometers of land at the confluence of the Volga River and the Kama River, Russia’s two largest waterways.
The republic has a population of 3.8 million and boasted 1.4 trillion rubles ($47 billion) of Gross Regional Product in 2012, a 5.5% increase over the previous year, and more than double the GRP of 483 billion rubles posted in 2005. Foreign Direct Investment into Tatarstan totaled $577 million in 2012.
This presentation gives an overview of Tatarstan's economy and investment opportunities.
Understanding User Needs and Satisfying ThemAggregage
https://www.productmanagementtoday.com/frs/26903918/understanding-user-needs-and-satisfying-them
We know we want to create products which our customers find to be valuable. Whether we label it as customer-centric or product-led depends on how long we've been doing product management. There are three challenges we face when doing this. The obvious challenge is figuring out what our users need; the non-obvious challenges are in creating a shared understanding of those needs and in sensing if what we're doing is meeting those needs.
In this webinar, we won't focus on the research methods for discovering user-needs. We will focus on synthesis of the needs we discover, communication and alignment tools, and how we operationalize addressing those needs.
Industry expert Scott Sehlhorst will:
• Introduce a taxonomy for user goals with real world examples
• Present the Onion Diagram, a tool for contextualizing task-level goals
• Illustrate how customer journey maps capture activity-level and task-level goals
• Demonstrate the best approach to selection and prioritization of user-goals to address
• Highlight the crucial benchmarks, observable changes, in ensuring fulfillment of customer needs
Event Report - SAP Sapphire 2024 Orlando - lots of innovation and old challengesHolger Mueller
Holger Mueller of Constellation Research shares his key takeaways from SAP's Sapphire confernece, held in Orlando, June 3rd till 5th 2024, in the Orange Convention Center.
Zodiac Signs and Food Preferences_ What Your Sign Says About Your Tastemy Pandit
Know what your zodiac sign says about your taste in food! Explore how the 12 zodiac signs influence your culinary preferences with insights from MyPandit. Dive into astrology and flavors!
How to Implement a Real Estate CRM SoftwareSalesTown
To implement a CRM for real estate, set clear goals, choose a CRM with key real estate features, and customize it to your needs. Migrate your data, train your team, and use automation to save time. Monitor performance, ensure data security, and use the CRM to enhance marketing. Regularly check its effectiveness to improve your business.
At Techbox Square, in Singapore, we're not just creative web designers and developers, we're the driving force behind your brand identity. Contact us today.
Top mailing list providers in the USA.pptxJeremyPeirce1
Discover the top mailing list providers in the USA, offering targeted lists, segmentation, and analytics to optimize your marketing campaigns and drive engagement.
Recruiting in the Digital Age: A Social Media MasterclassLuanWise
In this masterclass, presented at the Global HR Summit on 5th June 2024, Luan Wise explored the essential features of social media platforms that support talent acquisition, including LinkedIn, Facebook, Instagram, X (formerly Twitter) and TikTok.
Discover timeless style with the 2022 Vintage Roman Numerals Men's Ring. Crafted from premium stainless steel, this 6mm wide ring embodies elegance and durability. Perfect as a gift, it seamlessly blends classic Roman numeral detailing with modern sophistication, making it an ideal accessory for any occasion.
https://rb.gy/usj1a2
LA HUG - Video Testimonials with Chynna Morgan - June 2024Lital Barkan
Have you ever heard that user-generated content or video testimonials can take your brand to the next level? We will explore how you can effectively use video testimonials to leverage and boost your sales, content strategy, and increase your CRM data.🤯
We will dig deeper into:
1. How to capture video testimonials that convert from your audience 🎥
2. How to leverage your testimonials to boost your sales 💲
3. How you can capture more CRM data to understand your audience better through video testimonials. 📊
Digital Transformation and IT Strategy Toolkit and TemplatesAurelien Domont, MBA
This Digital Transformation and IT Strategy Toolkit was created by ex-McKinsey, Deloitte and BCG Management Consultants, after more than 5,000 hours of work. It is considered the world's best & most comprehensive Digital Transformation and IT Strategy Toolkit. It includes all the Frameworks, Best Practices & Templates required to successfully undertake the Digital Transformation of your organization and define a robust IT Strategy.
Editable Toolkit to help you reuse our content: 700 Powerpoint slides | 35 Excel sheets | 84 minutes of Video training
This PowerPoint presentation is only a small preview of our Toolkits. For more details, visit www.domontconsulting.com
Building Your Employer Brand with Social MediaLuanWise
Presented at The Global HR Summit, 6th June 2024
In this keynote, Luan Wise will provide invaluable insights to elevate your employer brand on social media platforms including LinkedIn, Facebook, Instagram, X (formerly Twitter) and TikTok. You'll learn how compelling content can authentically showcase your company culture, values, and employee experiences to support your talent acquisition and retention objectives. Additionally, you'll understand the power of employee advocacy to amplify reach and engagement – helping to position your organization as an employer of choice in today's competitive talent landscape.
2. Content
Overview of the Russian market
Key drivers and opportunities
Legal framework
Overview of Tatarstan and its market
Success stories from Tatarstan
Kazan Smart City
invest.tatarstan.ru
3. Impressive History
Nikolai Basov (1922 - 2001)
Russian physicist whose
pioneering work led to the
invention of the laser.
invest.tatarstan.ru
Mikhail Lomonosov (1711-1765)
Created the system of higher
education in Russia
Dmitri Mendeleev (1834-1907) -
arranged the 63 known elements
into a periodic table based on
atomic mass and also invented
40° vodka formula.
Ivan Pavlov (1854 - 1929)
The first Russian Nobel Prize
laureate in theoretical medicine.
He became famous for his
research on the regulatory effect
of the nerves.
Alexander Popov (1859-
1905)
In 1895 he developed the
first radio-receiver
4. Overview of Russia
Huge and growing
market
Developed
infrastructure
Excellent
macroeconomic
situation
Legal reform aimed to
improve health care
industry and
encourage local
production
Rising purchasing
power of the people
Aging population
Governmental
support
Customs union with
Belarus and
Kazakhstan
Accession to the WTO
as a guarantee for
transparent
environment
invest.tatarstan.ru
5. Main Opportunities in the Russian Market
growing demand for
pharmaceuticals
produced locally
opportunities for
high-cost drugs,
particularly in the
state-financed
programs
growth of local
R&D and biotech
for innovative
drugs
government support to
foster growth of the
local pharmaceutical
industry
growing
expenditures on
state programs
on federal and
state level
invest.tatarstan.ru
6. The Key Drivers of the Market
Governmental Support
The Russian Healthcare Development Program 2020 (aka Pharma 2020) substantially amends
legal framework of the Russian healthcare market and significantly raises state expenditure on
the sector. The legal changes, above all, aim to encourage local production of pharmaceuticals.
Increase of Consumption
In comparison with the Western markets the per capita spending on pharmaceuticals remains
five to seven times smaller. This low consumption level is not sustainable and the market is
destined to further expansion fueled by increase of both purchasing power and awareness of
more healthy life style.
Demographic Situation
Russia’s gradually aging population is another significant growth driver of the health care
industry. Life expectancy at birth will increase to 75 years in 2020 from the current 69 years.
Medical Insurance
Insurance is expected to have significant impact on the commercial retail segment due to its
dramatic increase in the next years.
Source: World Bank.
Frost & Sullivan, Changes in the Russian Pharmaceutical Market Following
Introduction of 2020 Governmental Reforms.
invest.tatarstan.ru
7. GDP Per Capita Growth in Russia
0
2000
4000
6000
8000
10000
12000
14000
16000
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
GDP per capita (current US$)
GDP per capita (current
US$)
Source: World Bank
invest.tatarstan.ru
8. The Federal Government Expenditure on
Healthcare Sector
0
10
20
30
40
50
60
70
80
State expenditure (billions USD)
2009
2015
2020
Source: Frost & Sullivan, Changes in the Russian Pharmaceutical Market
Following Introduction of 2020 Governmental Reforms.
invest.tatarstan.ru
9. Sales in Russia - Demand for pharmaceuticals will
double in next 10 years
0
5
10
15
20
25
30
35
40
45
50
Sales in 2011 Projected sales in 2020
US$ billions
US$ billions
Source: Business Monitor International
Market growth is expected to be around 15% annually.
invest.tatarstan.ru
10. Patented versus Generic Products
Generics will play main role in driving up
pharmaceutical sales
Additional spending on
patented products
(2020)
Additional spending on
generics (2020)
Source: Business Monitor International
invest.tatarstan.ru
11. Innovative Pharmaceuticals
30% of Drugs are state-
funded
It encompasses high-cost
innovative products
(treatment of tuberculosis,
HIV, cancer, etc.)
Stable business climate for
high-cost pharmaceuticals
development, production
and sales
The Russian market as a whole is driven
rather by generic low cost products (out-
of-pocket expenditure). However, about
30% of pharmaceuticals purchase is
funded by the state and thus guarantees
stable and steady income for innovative
medical and biotech products sellers.
invest.tatarstan.ru
12. Pharma 2020 Investment
Program Until 2020 5 key goals of the investment
- Facilitation of production of
pharmaceuticals within the country
- Development of R&D facilities
- Production and commercialization of
innovative medical products
- Increase of export potential (8 times)
- Training of scientific medical
personnel
The Russian Government will pour 4.2 billion USD into
Modernization of Healthcare and Biotech Industries
Volume of investment ($ billion)
Medical R&D projects 3.2
Transition to GMP (Good
Manufacturing Practice)
0.9
Staff training and
infrastructure development
0.1
Total 4.2
Source: Frost & Sullivan, Changes in the Russian Pharmaceutical Market
Following Introduction of 2020 Governmental Reforms.
invest.tatarstan.ru
13. Legal Framework Reform
Significant
increase in
government
spending
More transparent,
fair and efficient
market
Preferences to local
production over
imports
The reform of the pharmaceutical industry which was initiated by the Government
in 2008 is still actively progressing. The year 2012 saw the adoption of a number
of highly important legislative acts as well as amendments and corrective
adjustments to existing industry legislation.
Source: Ernst & Young: Survey of the pharmaceutical industry in Russia, 2012; Frost
& Sullivan, Changes in the Russian Pharmaceutical Market Following Introduction of
2020 Governmental Reforms.
invest.tatarstan.ru
Goals (2020)
Increase quality and availability of
healthcare
Stop population decline
Increase life expectancy at birth to 75 years
Decrease infant mortality by 20% and
maternal mortality by 15%
Decrease tobacco consumption by 25% and
the consumption of alcohol by 9 litres per
capita/year
14. Compulsory Medical Insurance Significant
Growth in Volume in Russia
0
200
400
600
800
1000
1200
2010 2011 2012 2013 2014
billion rubles
billion rubles
Source: Federal Service for Financial Markets
Value given in accordance with Federal Law No. 370-FZ of 30 November 2011 “Concerning the Budget of the
Federal Compulsory Medical Insurance Fund for 2012 and the Planning Period 2013 and 2014”.
The proportion of compulsory medical insurance as a share of GDP will move up from
3.56% to 5.5%
invest.tatarstan.ru
15. Volume of State Healthcare Expenditure and
Its Growth in Russia
Indicator 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020
Expendi
tures
(billion
rubbles)
1 933 2 230 2 773 2 993 4 238 4 505 4 789 5 090 5 411 5 752
Increase
%
- 15 24 8 42 6 6 6 6 6
Proporti
on of
GDP
3.56 3.80 4.28 4.13 5.50 5.50 5.50 5.50 5.50 5.50
Source: The Ministry of Finance of the Russian Federation
invest.tatarstan.ru
16. Russian government supports local
productions over imports
2012
Foreign
production
Domestic
production
2020
Foreign
production
Domestic
production
The overriding goal of the Pharma 2020 is to secure that at least 50% of
the pharmaceuticals (value terms) circulated in the Russian market are of
domestic origin.
Source: Cegedim. Emerging Markets Today and Tomorrow: Insights of
Healthcare, Pharmaceuticals and Future Trends in the BRIC Landscape.
invest.tatarstan.ru
17. Amended legal framework encourages to
localize production in Russia
0% 20% 40% 60% 80% 100%
Other
Despite state support, Russian manufacturer's share
of the market will decrease
State support will favor growth in Russian
manufacturer's share of the market
State policy will encourage the acquisition of Russian
companies by foreign manufacturers
State policy will encourage foreign manufacturers to
establish production in Russia
2012
2010
Source: Ernst & Young: Survey of the pharmaceutical industry in Russia,
2012
Executives, industry experts and analysts believe:
invest.tatarstan.ru
18. Clinical Trials
A bill drafted by the Federal Anti-Monopoly Service in March
2012 suggests the abolition of the requirement for local
clinical trials. Such a change implies:
• reduction of the time taken to introduce a medicinal
product to the market
• decrease in expenditure on development of a medical
product
• lowering the eventual cost of the product
• reducing red tape and hassle free introduction of new
products
Source: Ernst & Young: Survey of the pharmaceutical industry in Russia, 2012
invest.tatarstan.ru
19. Procurement of Goods for Public Needs
• Price preferences: In an auction, if a supplier submitting the lowest bid offers
to supply products that are not of Russian or Belarusian origin, the final
contract price paid to the supplier will be reduced by 15%. Similarly, in a
tender, if the winner offers products of Russian or Belarusian origin, the final
contract price paid to the winner will be increased by 15%.
• Selection preferences: Where the same terms and conditions are offered by
two or more suppliers in a state tender, the government will be required to
award the contract to the supplier that offered products of Russian or
Belarusian origin.
The Law No. 211 on Procedures for Admitting Goods Originating from Foreign Countries for the
Procurement of Goods for Public Needs significantly favors local manufacturers in government
procurement.
Source: http://www.lexology.com/library/detail.aspx?g=7fe187d5-6a21-4874-b79d-
d7634dca76ae
invest.tatarstan.ru
20. Russia is joining the world economy
• WTO membership ensures greater market access
for Russian exports and guarantees stable, rule-
based trade relations
• Russia is currently negotiating a free trade
agreement with the European Union
• Currently has bilateral free trade agreements with
Armenia, Georgia, Kyrgyzstan, and Ukraine
• Duty-free access to > 226 million consumers
(Сustom Union with Belarus and Kazakhstan)
invest.tatarstan.ru
21. Recent investments made by pharmaceutical
and biotech multinationals in Russia
Company Description
AstraZeneca, Teva, Novo Nordisk, Servier, Nycomed Investment in the construction of a production facility.
GalaxoSmithKline
Local company Binnopharm will produce its innovative
pharmaceuticals.
Orion, Stada, Sanofi-Aventis, Gedeon Richer
Full acquisition or acquisition of a controlling stake of a
local company.
Johnson & Johnson Enlargement of its production plant in Russia.
Genzyme Joint research project with ChemRar.
Pfizer
An agreement with Russian biopharmaceutical company
Petrovax to manufacture innovative vaccines.
Novartis
Developed partnership focused on local manufacturing
and R&D.
Source: Frost & Sullivan, Changes in the Russian Pharmaceutical Market
Following Introduction of 2020 Governmental Reforms.
invest.tatarstan.ru
22. Market Summary
Opportunities
Localization of Production and R&D facilities Profitable Sales
Outcome
Increase of Pharmaceutical Spending
Developed Healthcare Industry Infrastructure
and Qualified Labor Force
Market Conditions
Government Support Growing Personal Income
invest.tatarstan.ru
23. Tatarstan
One of the most economically developed regions of the Russian
Federation
Strategic location in the heart of Russia’s consumer basin (seven
of Russia’s 11 largest cities, or more than 50% of the country’s
population, lies within 1000 kilometers)
Investor-friendly and red tape free investment environment
invest.tatarstan.ru
25. Pharmaceutical Market in Tatarstan
Tatarstan pharma market has been experiencing significant
growth in the last years, in particular pharmacy retail sector.
Main market indacators
Growth of market in terms of
value in 2012
11.8%
The size of the market 924 billion rubles
Retail sector growth 13%
Consumption of
pharmaceuticals in Tatastan
compared to Russian average
21% higher
The decrease in sales of pharmaceutical units suggests decline in the demand
for old drugs and the growing popularity of innovative products.
invest.tatarstan.ru
26. invest.tatarstan.ru
People employed in
healthcare industry
Number
Healthcare staff 48,394
Doctors 12,522
Nurses 35,872
Graduates in healtcare
majors/year
600 – 1,100
Doctors and nurses per 10,000
people
Doctors 32.9
Nurses 95.3
27. Public-private Parnership Case Study
• an educational project designed to set up high
standards in postgraduate medical training in
effective use and implementation of medical
technologies
• the medical personnel receives training on how to
capitalize on accurate usage of medical technologies
to improve the efficiency of health care
• the first instutution of its kind in the Russian
Federation
• the center closely cooperates with one of the leading
multinational pharmaceutical companies Johnson &
Johnson and thus is an excellent success story of
public-private partnership in Tatarstan
• more than 500 participants from 28 regions of the
Russian Federation have been trained in the center
http://www.kazanmedcenter.com/
http://www.jnj.com/
Kazan Center of High Medical Technologies and Johnson & Johnson
invest.tatarstan.ru
28. Kazan Medical Instruments Plant
invest.tatarstan.ru
The largest manufacturer of medical
instruments both in Russia and in
Europe.
Products are well known in Russia,
the CIS countries, the USA, Germany,
Israel, Greece, Egypt, Australia,
Sweden, Japan and other countries.
Enormous production capacity
enables the company to deliver high-
quality products at a competitive
price.
http://www.kmiztrade.ru/en/about
29. Tatchempharmpreparaty Company
• one of the largest manufacturers of pharmaceuticals and surgical suture
materials in the Russian Federation and the only producer of surgical gut
(catgut)
• provides licensed and contract manufacturing of pharmaceutical products for
our foreign partners
• provides full support in arranging contract research, conducting both pre-
clinical and clinical trials, registration of medicines in the Russian Federation
and CIS countries as well as distribution
• their manufacturing facilities comply with international GMP (good
manufacturing practice) standards
• http://www.tatchempharm.ru/
invest.tatarstan.ru
30. KIR Company
Area of Activity
complex automation and implementation of innovative
technologies in healthcare (software)
Offices
Moscow, Prague, Kiev, Nizhniy Novgorod, Kazan,
Yekaterinburg and Orenburg
Mission
to create a solid foundation for development and prosperity
by means of implementation of innovative technologies
http://kirkazan.ru/
invest.tatarstan.ru
31. AVA Kazan
a clinic and fertility center which belongs to international network of clinics ABA (in
Russia first clinic opened in St. Petersburg)
one of the leading worldwide centers for egg donation and embryo donation
cooperates with the Finnish network of clinics „Mihilyaynen“
highly-skilled and international medical staff
clinics: AVA-Tampere and AVA-Turku in Finland, AVA-Lisbon in Portugal, AVA-Riga in
Latvia, in Russia - St. Petersburg and Kazan
http://www.avakazan.ru/
http://www.avapeter.com/en/about/
invest.tatarstan.ru
32. Kazan State Medical University
KSMU is one of the most famous and most
respected centers of medical education and
science in Russia. The teaching staff and
graduates of the University have made a
significant contribution to global and
domestic medicine.
is very attractive for foreign students - every
tenth student comes from abroad, every fourth
student is from the other region of Russia
is a recognized leader in the country in
developing and implementing new
educational methods
represents the leading scientific schools of
Russia with true capability to effectively
implement the results of research into
practice
http://www.kazansmu.com/
• 5500 students
• 8 Faculties
• 64 Departments
• 1500 staff members
invest.tatarstan.ru
33. Success Story of Foreign Company - Favea
• FAVEA is a leading European pharmaceutical engineering
company based in the Czech Republic.
• The company specializes in design and construction of:
pharmaceutical and biotechnological plants, Medical and
healthcare centers, Medical device plants.
• Favea is most active in Russia (including Tatarstan) and the CIS
countries, where successfully implemented more than 40 turnkey
projects for the major pharmaceutical manufacturers.
• Favea has been implementing GMP solutions in the Russian
market for nearly 20 years
• Favea provides design and construction solutions for Tatar
company TATCHEMPHARMPREPARATY:
- 2006-2007– Design of the production of tablets, sterile
ointments, gels, storage of raw materials.
- 2007-2008 – Reconstruction of the production of solid dosage
forms, turnkey contract, and validation.
http://eng.favea.org/
invest.tatarstan.ru
34. Favea’s awards
The President of the Republic of Tatarstan
Rustam Minnikhanov has honored FAVEA
with the national award – for the mutually
beneficial cooperation with Tatarstan
enterprises and strenghtening social and
cultural relations between Tatarstan and
the Czech Republic.
FAVEA was honored with award for
the best business project.
FAVEA project "Construction of the medicines
innovation research and development center„
was awarded in the category of „Best
Innovation Infrastructure".
invest.tatarstan.ru
35. Institute of Fundamental Medicine and
Biology of Kazan Federal University
one of the leading educational institution
in Russia in the fields of medicine and
biology
more than 1400 students, many of them
foreigners
internship program cooperation with the
best research centers in 20 countries
(Germany, France, Turkey, Austria, Japan,
Poland, China, etc.)
KFU is the best University in Volga region
and belongs to 18 best universities in
Russia according to the QS World
University Ranking.
http://www.kpfu.ru/main_page?p_sub=16
invest.tatarstan.ru
36. Republican Clinical Hospital
The autonomous public health care
institution Republican Clinical Hospital of
the Republic of Tatarstan is the largest
diversified medical institution of the
Republic of Tatarstan.
Annually more than 30 thousand patients
receive institutional care; over 18
thousand surgeries are executed; more
than 250 thousand visits are registered
http://en.rkbrt.ru/history/
invest.tatarstan.ru
37. Kazan Scientific Research Institute of
Epidemiology and Microbiology
• four research laboratories
• diagnostic clinic with focus on
infectious and allergic diseases
• development of rational schemes of
immunotherapy
• testing of pharmaceuticals
• provides expertise and scientific
support to the doctors on current
issues in allergy and immunology
invest.tatarstan.ru
38. Kazan Smart City
Kazan Smart City is being developed to
spur investment into four target
economic clusters in order to diversity
and modernize Tatarstan economy
through nurturing the growth of new
high-value added sectors.
Kazan Smart City is a Global Smart Sustainable City where there will be the Centre of
Excellence for International Business & Knowledge Development that will create a
Sustainable Economic Region and High Quality of Life.
Kazan Smart City in Numbers
KSC Gross Development Value: 10 bln.
USD
Total area: 650 ha
Population: 59,000
Jobs created: 39,000
Tourist visits per year: 337,000
Gross Floor Area: 7mln. M2
Residential: 2.7mln m2
Retail: 0.8mln m2
Office: 1.2mln m2
Hotel: 0.2mln m2 (5 units, 1 320 rooms)
Enterprise: 1.3mln m2
Institution: 819th m2
invest.tatarstan.ru
39. Fiscal Preferences for Medical Manufacturing
in Kazan Smart City Special Economic Zone
Taxes General rate
Rate for Kazan Smart City
Residents
Rate for
Technology
precinct
Value Added Tax 18% 18% 18%
Corporate Tax 20% 15.5% 2 – 15.5%
Personal Income Tax 13% 13% 13%
Social Insurance
Contribution
30% 30% 14 – 28%
Land Tax 1.5% 0% 0%
Property Tax 2.2% 0.01% 0%
Transport Tax Depends on engine
power
0% 0%
The Russian Federation has signed an agreement with more than 70 countries to avoid double
taxation.
invest.tatarstan.ru
40. Golden Opportunity is Here Right Now
Grasp the
Huge
Windfall
Produce
in Kazan
Smart
City
Sell in
Entire
Russia
invest.tatarstan.ru